Ratings for Pacific Biosciences (NASDAQ:PACB) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1.89, with a high estimate of $3.00 and a low estimate of $1.25. A negative shift in sentiment is evident as analysts have decreased the average price target by 14.09%.

Breaking Down Analyst Ratings: A Detailed Examination

The standing of Pacific Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into Pacific Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Pacific Biosciences analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Pacific Biosciences

Unraveling the Financial Story of Pacific Biosciences

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Negative Revenue Trend: Examining Pacific Biosciences's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -4.27% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Pacific Biosciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1146.81%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): Pacific Biosciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -142.44%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Pacific Biosciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -40.17%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 7.63, caution is advised due to increased financial risk.

The Core of Analyst Ratings: What Every Investor Should Know

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.